Acurx Pharmaceuticals LLC (ACXP)
Acurx Pharmaceuticals LLC is a clinical-stage biopharmaceutical company focused on developing antibiotics for bacterial infections in the United States. Its lead candidate, ibezapolstat, uses a novel mechanism of action aimed at the polymerase IIIC enzyme and is being evaluated in a Phase 2b clinical trial for clostridium difficile infections. The company is also advancing ACX-375C, an oral and parenteral antibiotic candidate designed to address gram-positive bacteria, including MRSA, VRE, and drug-resistant Streptococcus pneumoniae, as well as B. anthracis. Incorporated in 2017, Acurx is headquartered in Staten Island, New York.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ACXP
|
$1.93
|
42.2% Upside
|
Undervalued
|
$17 1,150.0% Upside
|
Not available
|
Bargain
|
Fair
|
0.0%
|
November 18, 2026
|
0.9x
|
7.167 M
|
-3.647 M
|
0.0%
|
97.6%
|
-17.1
|
82.4%
|
